Specialty Xenograft and Gene Editing Technology & CRO Services
Whether your focus is on xenograft/PDX drug efficacy studies,
gene editing, or research model creation, our team can help boost your preclinical research.
Trusted By Leading Biotechnology Companies
Hera BioLabs is a full-service CRO, offering a broad range of in vivo studies in both mouse and rat models. With our state-of-the-art facility, we can complete your in vivo efficacy tumor xenograft or PDX model study in your preferred mouse model or our proprietary SRG OncoRat®.
The SRG OncoRat® is the first commercially available highly immunocompromised rat model, which has been validated for oncology and used routinely for human xenograft studies.
Our comprehensive xenograft efficacy services use the SRG OncoRat® platform as well as NSG mice and other mouse tumor models. Dozens of cancer cell lines and PDX models have been validated for immediate screening and we also routinely establish new tumor models for our clients.
Whether your research calls for a targeted knockout, base-pair edit or gene expression, our unique Cas-CLOVER targeted nuclease and piggyBac transposase gene integration technologies have you covered.
Leverage our proprietary suite of gene editing tools and our teams experience in over 75 cell lines to make your cell line engineering projects a success.
Need a custom gene edited or transgenic rat or mouse model? From design to delivery we work with your team to create animal models tailored for your pre-clinical research.
Dedicated to ensuring the integrity of our science.
We love helping our clients streamline their preclinical research process and achieve
exceptional results.
“The tumor uptake rate was to 80-100%, which is a huge advantage because what we could achieve as a statistical significance with 8-12 mice, can be achieved with 5-6 OncoRats.”
Ramesh Narayanan, Ph.D.
Associate Professor of Medicine & Hematology University of Tennessee Health Science Center
“(The) Cas-CLOVER hybrid gene editing system fuses a functionally inactive Cas9 to the site-specific nuclease, Clo51. Cas-CLOVER is targeted using a set of two distinct gRNAs, operating like CRISPR-Cas9, but (the) system has the exquisite specificity of type IIS nucleases and causes no or very few off-target mutations. We can use this high-fidelity system to safely develop off-the-shelf CAR T-cell products.”
Devon H. Shedlock, Ph.D.
Vice President, Preclinical Development, Poseida Therapeutics
Our research and platform technologies have been presented in leading scientific publications.
Stay informed with our latest R&D, model developments, and industry trends on our blog.
Contact us to learn more about our CRO services for oncology research.